JP2021500406A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500406A5
JP2021500406A5 JP2020543406A JP2020543406A JP2021500406A5 JP 2021500406 A5 JP2021500406 A5 JP 2021500406A5 JP 2020543406 A JP2020543406 A JP 2020543406A JP 2020543406 A JP2020543406 A JP 2020543406A JP 2021500406 A5 JP2021500406 A5 JP 2021500406A5
Authority
JP
Japan
Prior art keywords
tcr
cancer
tumor
specific
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020543406A
Other languages
English (en)
Japanese (ja)
Other versions
JP7289311B2 (ja
JP2021500406A (ja
Filing date
Publication date
Priority claimed from GBGB1717578.7A external-priority patent/GB201717578D0/en
Application filed filed Critical
Publication of JP2021500406A publication Critical patent/JP2021500406A/ja
Publication of JP2021500406A5 publication Critical patent/JP2021500406A5/ja
Application granted granted Critical
Publication of JP7289311B2 publication Critical patent/JP7289311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020543406A 2017-10-26 2018-10-22 新規t細胞受容体 Active JP7289311B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1717578.7 2017-10-26
GBGB1717578.7A GB201717578D0 (en) 2017-10-26 2017-10-26 Novel T-cell receptor
GB1806155.6 2018-04-16
GBGB1806155.6A GB201806155D0 (en) 2017-10-26 2018-04-16 Novel t-cell receptor
PCT/GB2018/053045 WO2019081902A1 (en) 2017-10-26 2018-10-22 NEW LYMPHOCYTE RECEPTOR T

Publications (3)

Publication Number Publication Date
JP2021500406A JP2021500406A (ja) 2021-01-07
JP2021500406A5 true JP2021500406A5 (cg-RX-API-DMAC7.html) 2021-11-25
JP7289311B2 JP7289311B2 (ja) 2023-06-09

Family

ID=60580240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543406A Active JP7289311B2 (ja) 2017-10-26 2018-10-22 新規t細胞受容体

Country Status (17)

Country Link
US (2) US11725039B2 (cg-RX-API-DMAC7.html)
EP (2) EP3700925B8 (cg-RX-API-DMAC7.html)
JP (1) JP7289311B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200078497A (cg-RX-API-DMAC7.html)
CN (1) CN111278855B (cg-RX-API-DMAC7.html)
AU (2) AU2018356944A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020007880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3077635A1 (cg-RX-API-DMAC7.html)
DK (1) DK3700925T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091015A1 (cg-RX-API-DMAC7.html)
ES (1) ES2907819T3 (cg-RX-API-DMAC7.html)
GB (2) GB201717578D0 (cg-RX-API-DMAC7.html)
IL (1) IL274025A (cg-RX-API-DMAC7.html)
MX (1) MX2020004334A (cg-RX-API-DMAC7.html)
PL (1) PL3700925T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202002537WA (cg-RX-API-DMAC7.html)
WO (1) WO2019081902A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
EP4090969A1 (en) * 2020-01-16 2022-11-23 Universität Basel Mr1 ligands and pharmaceutical compositions for immunomodulation
WO2021250511A1 (ko) * 2020-06-10 2021-12-16 주식회사 유틸렉스 Mr1에 결합하는 t-세포 수용체 및 이의 용도
WO2022099297A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Multiplexed engineered ipsc and immune effector cells targeting solid tumors
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
WO2022244876A1 (ja) * 2021-05-20 2022-11-24 慶應義塾 抗腫瘍剤
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
KR20230088292A (ko) * 2021-12-10 2023-06-19 주식회사 유틸렉스 MR1 제한적 Panck T 세포 및 이의 제조방법
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
AU2018231405B2 (en) * 2017-03-07 2024-02-08 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor

Similar Documents

Publication Publication Date Title
CN109219445B (zh) 嵌合抗原受体修饰细胞治疗癌症的应用
JP6970974B2 (ja) 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ
JP2021058197A5 (cg-RX-API-DMAC7.html)
JP2022543702A5 (cg-RX-API-DMAC7.html)
TWI803835B (zh) 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
JP2021535749A5 (cg-RX-API-DMAC7.html)
CN115551537A (zh) 肿瘤细胞疫苗
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2017537622A5 (cg-RX-API-DMAC7.html)
JP2022537700A5 (cg-RX-API-DMAC7.html)
JP2021505190A5 (cg-RX-API-DMAC7.html)
JP2021501567A5 (cg-RX-API-DMAC7.html)
JP2022525099A5 (cg-RX-API-DMAC7.html)
CN113038939A (zh) 损害内施用pd-1抑制剂用于治疗皮肤癌
JP2023505192A5 (cg-RX-API-DMAC7.html)
KR102624844B1 (ko) 암의 향상된 치료
CN119486753A (zh) 个体化癌症表位及其使用方法
Nasrullah et al. Circulating RNAs in advanced colorectal cancer patients reveal increased expression of PD-1 with conventional CRC therapy
de Sostoa Pomés et al. Targeting the tumor stroma with a bispecific T-cell engager-armed oncolytic adenovirus
CN120590509A (zh) 分离的特异性结合MHC/Survivin表位复合体的肿瘤特异性TCR及其用途
Witt Cripto-1: potential target for cancer immunotherapy?!
JP2023545071A5 (cg-RX-API-DMAC7.html)